True transformation in healthcare requires innovation, collaboration, AND engagement from the HCP community. As pharma works to diligently nurture their relationship with the HCP community, pharma marketers are in a unique position to take charge of this transformation journey and provide HCPs with the education and resources they need to enhance quality of care. At Transforming Healthcare 2017, we build on the notion of "going beyond the pill," and continue to look at the innovative technologies advancing the industry, while exploring ways to create more connectivity and trust between pharma and HCPs- all for the good of the patient.
2017 speakers coming soon...
Julie Adrian has 20+ years of experience in the development and execution of healthcare marketing communications programs. She currently oversees Chandler Chicco Agency’s US operation, including Los Angeles, New York and Washington, D.C. and provides strategic counsel for marketing and corporate communications programs for pharmaceutical, biotech and device clients. Her work at the agency has ranged from business-to-business initiatives in infection prevention to professional education campaigns in ophthalmology to third-party celebrity programs for movement disorders and Parkinson’s disease to educational campaigns for allergic asthma to product launches and issues management for emerging consumer-facing brands. Julie’s areas of expertise include consumer health and disease awareness education. From oncology to women’s health, her experience includes programming in all phases of the product life cycle, including local and national media strategy, patient educational events, employer programs, third-party relationship development and programs, sales representative and employee communications integration, professional medical education, issues management, clinical trial recruitment and corporate reputation management.
Raj Amin has been a founder, early executive and advisor to disruptive technology companies in healthcare and media for over 20 years. He is currently Executive Chairman and Co-Founder at Mana Health, a technology company that unifies healthcare data across clinical systems, apps, and devices to enable a range of data-driven services that impact the cost and quality of healthcare. He is a Partner in OysterLabs, a boutique product strategy and development studio that services clients in healthcare and entertainment. Previously Raj was Founding CEO at HealthiNation, where he led its launch as the first cable-on-demand and online healthcare video network. Prior to this he was VP of Advertising and Content Markets at N2 Broadband, a leader in cable video-on-demand software that was acquired by Ericsson, Sr. Product Manager at ReplayTV, an early DVR pioneer, and led interactive TV partnerships at Scientific-Atlanta before its acquisition by Cisco. Raj is a Board Member at Musicians on Call, a leading non-profit that brings music to the bedsides of patients across the country. He has been an advisor to early stage companies and an investor in creative enterprises including Tony Award Winning productions of A Raisin in the Sun and Green Day’s American Idiot. Unfortunately for him, he missed the boat on Hamilton. Raj is a graduate of the University of Pennsylvania, with degrees from the Wharton School of Business and the Moore School of Engineering and Applied Science.
Jack Barrette is CEO of WEGO Health, a social network that empowers over 100,000 patient influencers to help others and to drive health innovation. Each of these patient leaders reaches an average of 15,000 followers each month through Facebook, Twitter, blogs and other online communities. WEGO Health connects companies to tens of millions of engaged health consumers through this trusted network of patient influencers for insights, recruiting, collaboration and activation. Previously, Jack was Category Development Officer for Health at Yahoo! Jack is a frequent public speaker and author who tweets @healthyjack.
Ian Bonzani is a Principal in the Real World Evidence Solutions group at IMS Health, where he is responsible for developing and implementing technology-enabled solutions to address the evolving evidence needs of the life sciences industry. In particular, Ian is an expert in creating therapeutic area evidence platforms – which integrate, harmonize, and securely access a variety of anonymous patient level data sources to fulfil a range of analytical needs of life science clients and wider healthcare collaborators. As part of this work, Ian has explored the use of health and behavioural data analyzed from social media sources as a means to enrich or fill evidence gaps seen with traditional observational research approaches. Ian’s background includes four years as a Consultant in the IMS Consulting Group in Europe, where he has supported the development of global pricing & market access strategies and constructing pre- and post-launch RWE plans across large and mid-size life sciences clients globally. Ian holds a PhD in Tissue Engineering from Imperial College in London and has a BSc in Biomedical Engineering from WPI in the US.
Pharmaceutical companies love to talk about innovation, especially as it pertains to the truly transformative science that underlines their medicines. But when it comes to innovation in other guises—as within the health-tech space—most organizations don't, or can't, walk the walk. Takeda, on the other hand, ranks among the few traditional pharma firms in which innovation exists outside the realm of the theoretical, and Bova is one of the people chiefly responsible for that. As director of the company's in-house Digital Accelerator, a kind of VC firm housed within Takeda's walls, Bova has pressed her peers to think big, to pursue “moon-shot ideas” as well as more incremental innovations. But getting to a place where that way of thinking is imbued in every individual at every level of the 33,000-strong company wasn't easy. Bova and her team first ventured out into the tech world, meeting with Google, Apple and IBM/Watson to get their take on health-tech innovation. They then did what Bova describes as a “lot of soul-searching” and put together a plan for the Takeda board that spelled out the necessary steps to create an environment in which the innovation mind-set would thrive. Around 18 months after the effort commenced, Bova reports that Takeda has been, well, transformed. “My goal is for everyone here to have the mind-set that we're a 33,000-person start-up,” she says. “You don't get to live 230 years, as we have, without constantly reinventing yourself and really looking hard for ways to innovate.
Jessica joined MicroMass in 2000 and leads a team of behaviorists in applying behavior change strategies to health communication programs for the life sciences industry. With a combined background in nursing and public health, Jessica has a passion for creating solutions that can change patient and healthcare provider behavior and improve health outcomes. Her leadership role within MicroMass has expanded to include the development of new products and services for health systems and accountable care organizations.
Dr. David Collymore is the Chief Medical Officer of Acacia Network. Dr. Collymore received his medical degree from the Howard University College of Medicine and an MBA from the George Washington University.
Anthony Costello is the Co-Founder and CEO of Mytrus and a leader in the area of clinical trials technology. For over 20 years, he has been developing disruptive innovations that can simplify clinical trials for patients, sites and sponsors. After beginning his clinical career in data management at Genentech, Costello has gone on to co-found several clinical and high technology start-up companies in Northern California including: Nextrials, Bazu Media (now Chronotrack), and Mytrus - a clinical research technology company building web and mobile applications for patients on clinical trials. He has been selected as one of the PharmaVoice Top 100 Most Inspiring People in Clinical Research, has served as Chairman of the Board for the Society for Clinical Data Management as well as on the Founding committee for the CDISC CDASH initiative and is currently a member of the editorial advisory board for Applied Clinical Trials magazine. He is a frequent author and presenter on topics related to the efficient use of technology and clinical research. He has a degree in Sociology from UC Berkeley.
Dr. Yechiel Engelhard is the founder and former CEO of Gecko Health Innovations, a Cambridge, MA, software and connected devices company which was acquired by Teva Pharmaceuticals in Summer 2015. The company developed a mobile apps and sensors, based on behavioral incentive tools, to help patients take control of their COPD or asthma disease. The system designed to support payers and providers with clinical and costs efficiencies. Gecko was named one of the best gadgets for asthmatic patients, by Frost & Sullivan, TEDMED and leading publications such as the Huffington Post, Wall Street Journal, Boston Business Journal, Wired, and the Boston Globe. After spending 16 years as a healthcare entrepreneur, a practicing physician, a researcher, and a medical officer in the Israeli Air Force Special Operations, currently Yechiel is leading new technology products development at Teva Pharmaceuticals. He has co-founded and worked with several medical and healthcare IT companies in Israel and the US, and he is a frequent speaker at industry events about mobile and connected devices in healthcare. Yechiel spends time mentoring teams at MIT, Harvard, and other global healthcare accelerators. Yechiel received an MD and MHA from Ben-Gurion University in Israel and an MBA from MIT Sloan School of Management.
Dave Fuehrer began his career as a corporate consultant and spent 10 years managing innovation for Pfizer, General Electric and many others. But being diagnosed with cancer twice in his twenties profoundly changed his perception about creating value to help others. Dave now serves on the Board of Stupid Cancer, the international organization that comprehensively addresses young adult cancer through advocacy, research, support, outreach, awareness, mobile health and social media. He has lead the launch and growth of Instapeer, a free mobile app for anyone affected by cancer to access instant, anonymous peer support. Dave believes that as patients, we are innovators and have the power to transform healthcare in big and meaningful ways. He received a BS in Communication and MBA in Technology Management from Rochester Institute of Technology. He completed Executive Education at Harvard in Building New Ventures and at MIT in Corporate Strategy. "Concern for man himself must be chief among his endeavors for technological innovation" - Albert Einstein
Bob’s curiosity about all manner of customer communications may lead some to think he suffers from chronic identity crisis. He began in account management but soon transitioned to copywriting and creative direction. He started and ran a small boutique agency for 12 years, but left that to head up Saatchi & Saatchi’s Consumer Healthcare unit. He embraces his pharmaceutical experience with brands like Plavix, Nexium, Enbrel, Crestor, and Ambien CR, but draws heavily from his experience with consumer packaged goods brands and business services like Fed Ex, Tylenol, Ivory Soap and Timberland. He dismisses any suggestion of identity drift, preferring to call it a case of insatiable curiosity. Bob is also a graduate of BJ Fogg’s Behavior Design Boot Camp.
Shelly Ikeme is currently the Director, Global Head of Market Access, HEOR & International Pricing at Baxter where she supports the global Surgical Care franchise. In Shelly’s current role at Baxter, she is tasked with the responsibility of developing and implementing the overall Surgical Care franchise global market access strategy through collaboration with country and international market access staff, marketing and medical affairs teams. Prior to Baxter, Shelly has served in various Health Economics role at Sanofi (Oncology) and Bristol Myers Squibb (Immunology), where she leveraged her health economics and outcomes research (HEOR) expertise in developing pharmacoeconomics studies that demonstrate economic and humanistic value and driving the communications of this value to the complete range of external stakeholders, including providers, payers, and policymakers. Shelly received both her Doctorate of Pharmacy and MBA degrees from Temple University and a Masters in Public Health in Health Economics & Policy from Johns Hopkins University. In May 2017, Shelly will be completing a PhD in Applied Health Economics & Outcomes Research from Thomas Jefferson University in Philadelphia.
A serial entrepreneur in connected medical devices and wearables, Sridhar has recently started a new company, Elemental Machines. Previously, Sridhar was a founder and director of Misfit, makers of elegant wearable products, which was acquired by Fossil in 2015. Prior to Misfit, he founded AgaMatrix, a blood glucose monitoring company that made the world’s first medical device connecting directly to the iPhone. AgaMatrix shipped 15+ FDA-cleared medical products, 2B+ biosensors, 6M+ glucose meters, with partnerships with Apple, Sanofi, and Walgreens. Sridhar holds over 30 US and international patents and received his Ph.D. from Cambridge University as a Marshall Scholar.
In 2007, Steve’s 13-year-old son, Alex, was diagnosed with scoliosis. The ensuing treatment required him to wear a big torso brace 22 hours per day to prevent the curve from getting worse, but it also prevented him from being able to bend over and put his own shoes on. Eventually, Steve had the idea to create “hands-free” shoes, so that Alex could independently put on his shoes while in the brace and regain some of the self-esteem he had lost because his parents had to do it for him. After years in development, obtaining two patents, sourcing manufacturing and garnering numerous awards along the way, Quikiks [pronounced Quick-Kicks] were finally launched in 2015 as the first fully supportive, totally hands-free operable shoes that securely fasten. Steve’s hope and the mission of his company, Hands-Free Inc., is that Quikiks can improve the quality of life and increase the independence and safety for the millions of people with various physical and cognitive conditions that make it difficult or impossible for them to do this simple task that so many of us take for granted. Steve has had a varied career. After receiving degrees in Electrical Engineering and Computer Science from The Cooper Union and New York University respectively, he worked as a robotics engineer in Japan. Then he came back to New York to manage his family’s retail cheese store, followed by opening his own gourmet food store and catering business. Steve is the President of the Board of Directors of Services for the Developmentally Challenged, a non-profit agency that provides residential and day habilitation services for people with disabilities. His long-term goal for Hands-Free Inc. is to open a Quikiks distribution center in NYC that will provide employment opportunities for people with disabilities.
Dr. Vishal Lala is an Assistant Professor of Marketing at the Lubin School of Business, Pace University. His research interests include consumer decision making, electronic media, and promotion. His publications have appeared in marketing and e-commerce journals such as Journal of Advertising Research, Journal of Interactive Marketing,, International Journal of Accounting Information Systems,, Journal of International Consumer Marketing, and International Journal of Retailing and Distribution Management. He has taught introductory marketing courses, quantitative courses such as interactive marketing, marketing engineering, and marketing research, and new technology courses such as e-commerce.
Aaron is a General Partner at dRx Capital, the joint investment company of Novartis and Qualcomm, focused on Digital Medicine. dRx catalyzes the success of digital medicine products, services, and business models by investing in early-stage companies and leveraging networks in Pharma, Mobile/IT, and the investment community. Before dRx, Aaron worked on technology strategy for clinical research within Novartis. This work has led him to conclude that mobile, cloud, and Health IT technologies provide transformative opportunities in the clinical research and pharmaceutical industries. Aaron has led projects building upon these themes across multiple Business Units within Novartis, often by collaborations or investments in early-stage partner companies. Previously, Aaron led laboratory teams at Novartis, investigating the biological bases for drug toxicity. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institutet, and completed his undergraduate studies at Cornell University.
Lynn O’Connor Vos is the CEO of greyhealth group (ghg), a global enterprise servicing the needs of a full spectrum of health and wellness companies. She is the first woman to develop and run a global health communications enterprise. A ‘healthy disruptor’ known for playing the evangelist role, Vos’ seminal speech at the Healthcare Businesswomen’s Association called on her big Pharma clients to face up to eroding trust and rebuild their reputation among consumers. Today, Vos is pointing the industry ‘back to basics’ — arguing that communication is the cure for people to make better decisions, adopt positive behaviors, and live healthier lives. A champion of using digital capabilities to improve the public health, Vos’ agency was the first healthcare agency to partner and develop prototypes to apply IBM Watson's cognitive computing to healthcare companies and their consumers. Medical Marketing & Media called her decision to join the data company’s ‘healthcare moonshot’ an example of Vos’ longstanding “appetite for innovation.”
BAKUL PATEL is Associate Director for Digital Health, at the Center for Devices and Radiological Health (CDRH), at the Food and Drug Administration (FDA). Mr. Patel leads regulatory policy and scientific efforts at the Center in areas related to emerging and converging areas of medical devices, wireless and information technology. This includes responsibilities for mobile health, health information technology, cyber security, medical device interoperability, and medical device software. Mr. Patel is the FDA liaison between the Federal Communications Commission (FCC) and the Office of the National Coordinator (ONC). Since its inception in 2013, Bakul chairs the International Medical Device Regulators Forum (IMDRF) “software as a medical device” working group, a global harmonization effort. Before joining FDA, Mr. Patel held key leadership positions working in the telecommunications industry, semiconductor capital equipment industry, wireless industry and information technology industry. His experience includes Lean Six Sigma, creating long and short-term strategy, influencing organizational change, modernizing government systems, and delivering high technology products and services in fast-paced, technology-intensive organizations. Mr. Patel earned an MS in Electronic Systems Engineering from the University of Regina, Canada, and an MBA in International Business from The Johns Hopkins University
Richard is a research psychologist who has consulted with pharmaceutical companies and their advertising and market research agencies for more than a decade. His work focuses on how how physicians make decisions about prescribing, how patients make decisions about adhering to treatment recommendations, and how US and European payors make decisions about pricing, reimbursement, and access. Over his career, Richard has interviewed hundreds to clarify how consumers think, feel, and behave, and to identify strategies for communicating value and changing behavior. He was a Director of Market Access Research at Adelphi Focus, part of the Omnicom group of companies, where he consulted on US and European reimbursement decision making. Also, Richard was VP, Director of Behavioral Insight for GSW Worldwide (part of inVentiv Communications), where he helped pharmaceutical marketing teams understand how payors, physicians, and patients process information about illnesses and treatments. Richard was a methodologist and program evaluator with a University of Pennsylvania-affiliated research institute where he consulted with commercial and US federal and state agencies on issues health services programming and utilization, pay-for-performance, and funding. He has taught measurement, research methodology, and statistics at the University of Pennsylvania and Saint Joseph’s University. Richard holds doctorate in professional and scientific psychology from the University of Pennsylvania.
Fred is a seasoned digital and multichannel marketer with nearly 20 years’ experience planning and implementing communications programs for clients in a range of industries and at leading agencies such as Ogilvy, Grey, R/GA, and Young & Rubicam. He is an expert in designing high-impact marketing campaigns that integrate behavioral insights, analytics, and emerging media into brand experiences. Fred has played an instrumental role in delivering strategic solutions across a broad range of therapeutic categories for many tier-one health care companies including AbbVie, AstraZeneca, GSK, Johnson & Johnson/Janssen, Merck, Novartis, Novo-Nordisk and Pfizer. A former attorney, Fred is a graduate of Columbia Business School’s Executive Development Program. As a doctoral candidate in marketing at Pace University, he is conducting research into the factors effecting how consumers set and attain health- and wellness-related goals. His expertise includes market research, audience insights, strategic planning, digital, social and mobile marketing, data analytics, user experience design, and cross-functional team leadership.
Valéry’s background is in the development of quantitative methods for decision making support. As the Global Director of HEOR Excellence at Novartis, he is responsible for piloting innovative methods and developments and he facilitates expert dialogues for continual operational excellence. His area of expertise covers a variety of topics including advance analytics methods, evidence synthesis as well as advanced usage of social media. His responsibilities also include boosting the optimisation of successful pilots by means of communication and internal consulting. Prior to Novartis, Valéry received his Ph.D. in Applied mathematics from Paris, school of Mines. Following his Ph.D, he worked for Hewlett-Packard where he developed his expertise in technology transfer and innovation management. Following his MBA at IESE he moved into consulting; during this period, he acquired experience on design and implementation of business processes and change management.
Dr. Leonard Saltz is Professor of Medicine at the Weill Medical College of Cornell University and Chief of the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan-Kettering Cancer Center, both in New York City. In addition to leading many investigational trials at Memorial Sloan-Kettering, he has served as principal investigator on several multicenter national and international clinical trials. He has authored over 200 peer reviewed articles, as well as numerous reviews, books, book chapters, and editorials. He has also written and spoken extensively about the rising costs and declining relative value of many of the newer anticancer therapies. Dr Saltz is a member of the NCCN Colorectal, Neuroendocrine, and Unknown Primary Guidelines Panels, the NCI Rectal/Anal Cancer Task Force, the GI Core Committee of the Alliance NCI cooperative group, and the ASCO Value in Cancer Care Task Force. He is also the Chairman of the Pharmacy and Therapeutics Committee at Memorial Sloan Kettering. Dr. Saltz received his undergraduate degree at Stanford University and his medical degree at Yale University. He completed his medical residency and his hematology/oncology fellowship at The New York Presbyterian Hospital/Cornell University Medical College.
Jane Sarasohn-Kahn is a health economist, advisor and trend-weaver to organizations at the intersection of health, technology and people. Jane founded THINK-Health after spending a decade as a health care consultant in firms in the U.S. and Europe. Jane’s clients are all stakeholders in health: technology, bio/life sciences, providers, plans, financial services, consumer goods, and not-for-profits. Jane also founded the Health Populi blog in 2007. Jane advises clients on strategy via environmental analysis, scenario and strategic planning, and health policy analysis. She is on the advisory boards of CanSurround, CAQH’s U.S. Health Efficiency Index, Cardeation Capital (the American Heart Association’s venture arm), GE Ventures, the Health 2.0 Conference, HealthBank, HIMSS Connected Health Committee, Intuit’s American Tax & Financial Center, the Society for Participatory Medicine, and WEGO Health. In her community, Jane also sits on the Board of The Clinic, a free clinic for residents, and is a member of the Development Commitment. Jane is a frequent speaker on consumers, health and technology, and is listed with AHA’s Speakers Express and Executive Speakers Bureau. Jane is a contributor to the Huffington Post and California HealthCare Foundation’s iHealthBeat.
Dr. Kathleen Starr holds a doctorate in Clinical Health Psychology from the University of Miami and completed a post-doctorate fellowship at Duke University Medical Center. Dr. Starr has worked in a wide range of healthcare settings ranging from academic medical centers, government agencies, to private multidisciplinary medical practices. She has over 18 years of experience in the life science industry translating behavioral insight into commercial strategy. As a health psychologist, Kathleen brings expertise in disease management, treatment adherence, and health outcomes in many therapeutic areas including oncology, diabetes, HIV, rheumatoid arthritis, cardiovascular disease, neurological conditions and chronic pain. She continues to work in the community with patients who are facing challenges associated with serious illness. Kathleen is passionate about improving the patient experience and leveraging the psychology of behavior to create patient-centered solutions throughout the product lifecycle.
Ronen Joined Teva Pharmaceuticals in September 2013 as Senior Vice President, Strategic Business initiatives. Under his areas of responsibilities at Teva are the Teva’s Patient technologies and Commercial Personalized Medicine & Diagnostics, as well as New Therapeutic areas under development. Prior joining Teva, Ronen worked at GE Healthcare where he lead the Pharma Segment in the Life Sciences division, and prior to that served as the Medical Diagnostic’s division Director of Market Development, where he developed and executed GE Healthcare’s in-vitro diagnostics market entry, resulted in the acquisition of 2 major reference laboratories, Clarient, a high-end oncology lab and SeqRight, a full service sequencing laboratory. Prior GE, Ronen served in several senior leadership roles in the pharmaceutical and diagnostics industry, including Chief Commercial Officer for Rosetta Genomics, a microRNA diagnostic company; VP, Investor Relations, Head of North America for Novartis Corporation; Head of Business Intelligence for Serono USA and Global Product Manager, Rebif, for Serono International in Geneva, Switzerland. Ronen holds a B.Sc in Biology from Bar-Ilan University in Ramat Gan, Israel and an MBA from Warwick Business School in the UK. He is based in Frazer, PA.
Amar Urhekar, a veteran of the Global McCann Health network, was promoted in 2014 to President, McCann Health Americas. Previously, he served as McCann Health’s Executive VP based in Singapore, leading its Asia Pacific network of 14 offices in nine countries. Under his leadership, McCann Health was named “Specialist Agency Network of the Year” by Campaign Asia magazine in four out of five successive years, and the magazine named him as 2012 Agency Head of the Year for the Japan/Korea markets. Amar’s 18-plus years’ experience spans across the healthcare communications spectrum, including marketing management in the pharmaceutical industry and mainstream advertising businesses. He began his career with McCann Health in 2000 when he founded the agency in India, which grew quickly into a two-office, 60-person operation. In 2004, he moved to become Managing Director of McCann Health Greater China, and in 2009 moved to President of Japan McCann Health group. In 2010 he was made head of the Asia Pacific region, along with the task of leading its flagship operations in Japan. In 2015, Amar made his biggest strategic move since taking the helm as President McCann Health Americas in 2014 by uniting McCann Health’s North American offices and a staff of more than 600 healthcare professionals from five companies to become McCann Health North America. Under Amar’s leadership, McCann Health North America has won multiple new assignments and expanded relationships with existing clients and is poised for the next stage of growth.
David is the founder and CEO of Fit4D, a company whose mission is to improve the lives of people with diabetes and chronic conditions, worldwide. David was diagnosed with Type 1 diabetes, at the age of 36, while training for a survival race. A veteran of numerous running and triathlons races (including Ironman triathlons consisting of a 2.4M swim, 112M bike and 26.2M run), David committed to rebuild his life and provide positive energy to the diabetes community while coping with the condition on a 24×7 basis. Beginning with shorter races, he gradually learned how to successfully race triathlons as a person with diabetes and within a year completed the famous Escape from Alcatraz Triathlon in San Francisco Bay. In 2003 and 2005, he raced Ironman triathlons again – though this time working through the delicate balance between food, nutrition and exercise. For both races, he also fundraised extensively on behalf of the Juvenile Diabetes Research Foundation’s (JDRF) New York City Chapter. In his journey as someone with diabetes, David has been fortunate to meet many incredible people with diabetes and their families. It is David’s personal passion to share his experiences, knowledge and positive energy with the diabetes community. With leadership experience in the technology sector at startup and public companies, David decided to devote his energies to helping people with diabetes. As CEO of Fit4D, David engages with executives at leading pharmaceutical and payer organizations in helping them achieve their business and patient goals. David has a BA in Computer Science and a MBA in Marketing.
* Subject to change
Get a sense of the changing tides in healthcare, and learn more about the needs and behaviors of HCPs and how to best engage them during their online user journey. Join the discussion! Attendees will have an opportunity to be active participants by guessing on stats in real time, using polling technology, as the presenters provide a data download on HCP behavior.
In this follow up to the State of the Union, we discuss in detail how data, tech, and medicine are transforming results for patient, provider and pharma. Discussion to include perspectives from the HCP and pharma marketer, data specialist and tech innovator.
How pharma can flip the script and provide more educational vs. promotional content to the healthcare community.
An opportunity to assess and benchmark your current content marketing strategies, and make improvement to future strategies.
A regulatory perspective on pharma marketing, and the symbiotic relationship between pharma, HCP and the patient.
A series of short power-packed pitches focused on transforming healthcare. Presenters in this session compete for industry bragging rights as they present their innovative industry transforming ideas!
A look at top performing channels and messaging formats.
Research shows that pharma marketing in the digital space in comparison to other industries is minimal at best; which suggests the industry may just be “checking a box.” This session looks at the ROI of digital marketing to HCPs.
Health tech innovation competition where finalists present their wares to industry “sharks” from biopharma disease and med tech.
MM&M Editorial and Advisory Boards select top “beyond the pill” poster submission and winner has a chance to share the outcomes of their case study.
Panel to include HCP, pharma marketers, and marketing agency/solution provider
DATE & TIME
Thursday, May 1
Top 40 Transformers Dinner
Groups (2- 5) Ticket
$395 (per person)
Purchase your tickets today! Click here to buy.